656
Views
34
CrossRef citations to date
0
Altmetric
Articles

The economic burden and health-related quality of life associated with systemic sclerosis in France

, , , &
Pages 238-246 | Accepted 10 Oct 2014, Published online: 18 Dec 2014

References

  • Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;2:152–7.
  • Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792–800.
  • Katsumoto TR, Whitfield ML, Connolly MK. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011;6:509–37.
  • Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437–44.
  • Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10.
  • Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311–18.
  • Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004;43:1129–37.
  • El Adssi H, Cirstea D, Virion J-M, Guillemin F, de Korwin J-D. Estimating the prevalence of systemic sclerosis in the Lorraine region, France, by the capture-recapture method. Semin Arthritis Rheum 2013;42:530–8.
  • Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997;27:73–84.
  • Minier T, Péntek M, Brodszky V, Ecseki A, Kárpáti K, Polgár A, et al. Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 2010;49:1920–8.
  • Bernatsky S, Hudson M, Panopalis P, Clarke AE, Pope J, Leclercq S, et al. The cost of systemic sclerosis. Arthritis Rheum 2009;61:119–23.
  • Hudson M, Thombs BD, Steele R, Panopalis P, Newton E, Baron M, et al. Health-related quality of life in systemic sclerosis: a systematic review. Arthritis Rheum 2009;61:1112–20.
  • Rannou F, Poiraudeau S, Berezné A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-Item Short Form Health Survey. Arthritis Rheum 2007;57:94–102.
  • Nguyen C, Poiraudeau S, Mestre-Stanislas C, Rannou F, Bérezné A, Papelard A, et al. Employment status and socio-economic burden in systemic sclerosis: a cross-sectional survey. Rheumatology (Oxford) 2010;49:982–9.
  • Bérezné A, Seror R, Morell-Dubois S, de Menthon M, Fois E, Dzeing-Ella A, et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res 2011;63:277–85.
  • Bérezné A, Nguyen C, Mouthon L. [Professional consequences of systemic sclerosis], in French. Presse Med 2013;42:1159–70.
  • Linertová R, Serrano-Aguilar P, Posada-de-la-Paz M, Hens-Pérez M, Kanavos P, Taruscio D, et al. Delphi approach to select rare diseases for a European representative survey. The BURQOL-RD study. Health Policy 2012;108:19–26.
  • Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy 2006;77:51–63.
  • Basic drugs and price information. Available from: www.codage.ext.cnamts.fr/codif/bdm_it/index_presentation.php?p_site=AMELI ( accessed 12 May 2014).
  • List of products and services. Available from: www.codage.ext.cnamts.fr/codif/tips/index_presentation.php?p_site=AMELI ( accessed 12 May 2014).
  • Common classification of medical procedures. Available from: www.ameli.fr/accueil-de-la-ccam/index.php ( accessed 12 May 2014).
  • National coding table of biologics. Available from: www.codage.ext.cnamts.fr/codif/nabm/index_presentation.php?p_site=AMELI ( accessed 12 May 2014).
  • National scale costs per GHM. Available from: www.atih.sante.fr/?id=000370000AFF ( accessed 23 March 2014).
  • Coldefy M, Com-Ruelle L, Lucas-Gabrielli V, Marcoux L. Access to health care in France at 1 January 2007. IRDES 2011;1:1–130.
  • van den Berg B, Brouwer WBF, Koopmanschap MA. Economic valuation of informal care. An overview of methods and applications. Euro J Health Econ 2004;5:36–45.
  • Tranmer JE, Guerriere DN, Ungar WJ, Coyte PC. Valuing patient and caregiver time: a review of the literature. Pharmacoeconomics 2005;23:449–59.
  • Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011; 20:1727–36.
  • Luo N, Li M, Chevalier J, Lloyd A, Herdman M. A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive systems. Qual Life Res 2013; 22:2237–43.
  • Gualtierotti R, Scalone L, Ingegnoli F, Cortesi P, Lubatti C, Zeni S, et al. [Health related quality of life assessment in patients with systemic sclerosis], in Italian. Reumatismo 2010;62:210–14.
  • Strickland G, Pauling J, Cavill C, McHugh N. Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EURQol-5D and FACIT-F assessment tools. Clin Rheumatol 2012;31:1215–22.
  • Müller H, Rehberger P, Günther C, Schmitt J. Determinants of disability, quality of life and depression in dermatological patients with systemic scleroderma. Br J Dermatol 2012;166:343–53.
  • Van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012; 15:708–15.
  • Oemar M, Janssen B. EQ-5D-5L user guide. Basic information on how to use the EQ-5D-5L instrument. EQ-5D 2013;1-28. Available from: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L_v2.0_October_2013.pdf (accessed 12 May 2014).
  • Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965;14:61–5.
  • Perneger TV, Combescure C, Courvoisier DS. General population reference values for the French version of the EURQol EQ-5D health utility instrument. Value Health 2010;13:631–5.
  • Lopez-Bastida J, Oliva-Moreno J, Perestelo-Perez L, Serrano-Aguilar P. The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain. BMC Health Serv Res 2009;9:55.
  • Lee WJ, Song K-H, Noh JH, Choi YJ, Jo M-W. Health-related quality of life using the EURQol 5D questionnaire in Korean patients with type 2 diabetes. J Korean Med Sci 2012; 27:255–60.
  • Chevreul K, Durand-Zaleski I, Gouépo A, Fery-Lemonnier E, Hommel M, Woimant F. Cost of stroke in France. Eur J Neurol 2013;20:1094–100.
  • Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;21:1617–29.
  • Door J. [Informative report in conclusion of the work by the mission of evaluation and control of the laws of social security funding for long-disease duration scheme], in French. Assemblée Nationale 2008. Available from: http://www.assemblee-nationale.fr/13/rap-info/i1271.asp (accessed 12 May 2014).
  • Cost of long-term illnesses. Available from: www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/affection-de-longue-duree-ald/cout/cout-des-ald-en-2009.php ( accessed 13 February 2014).
  • Le Garrec M., Bouvet M. [National health statistics 2012], in French. Sér Stat 2013;185:1–240.
  • Prices and purchasing power parities (PPP). Organization for Economic Cooperation and Development. Available form: http://www.oecd.org/std/prices-pp/PPP%20manual%20revised%202012.pdf (accessed 13 February 2014).
  • Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence Policy 2010;6:51–9.
  • Belotti Masserini A, Zeni S, Cossutta R, Soldi A, Fantini F. [Cost-of-illness in systemic sclerosis: a retrospective study of an Italian cohort of 106 patients], in Italian. Reumatismo 2003;55:245–55.
  • Mestre-Stanislas C, Poiraudeau S, Berezné A, Rannou F, Pagnoux C, Revel M, et al. Differences in patients with systemic sclerosis recruited from associations and tertiary care settings. Presse Med 2010;39:e205–9.
  • Kwakkenbos L, Fransen J, Vonk MC, Becker ES, Jeurissen M, van den Hoogen FHJ, et al. A comparison of the measurement properties and estimation of minimal important differences of the EQ-5D and SF-6D utility measures in patients with systemic sclerosis. Clin Exp Rheumatol 2013;31:50–6.
  • López-Bastida J, Linertová R, Oliva-Moreno J, Posada-de-la-Paz M, Serrano-Aguilar P. Social economic costs and health-related quality of life in patients with systemic sclerosis in Spain. Arthritis Care Res 2014;66:473–80.
  • Reher DS. Family ties in Western Europe: persistent contrasts. Popul Dev Rev 1998;24:203–34.
  • Vilaplana Prieto C, Jiménez-Martín S, García Gómez P. [Trade-off between formal and informal care in Europe], in Spanish. Gac Sanit SESPAS. 2011;25(Suppl 2):115–24.
  • Highest degree earned by age and sex in 2012. Available from: www.insee.fr/fr/themes/tableau.asp?reg_id=0&ref_id=NATCCF07235 ( accessed 27 August 2014).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.